Translational efforts targeting IFN-γ may enhance the probability of achieving more frequent durable responses from CAR T cell therapy in patients with hematologic malignancies and guide clinical trials of CAR T cells for solid tumor malignancies. This evidence concerns the gene IFNG and hematologic disorder.